menu
    • menu
    [{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Xicheng Jinrui Equity Investment Fund","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Series C Financing","leadProduct":"Lingdolinurad","moa":"Urate transporter protein","graph1":"Rheumatology","graph2":"Phase II","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Xicheng Jinrui Equity Investment Fund","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Atom Bioscience & Pharmaceutical \/ Xicheng Jinrui Equity Investment Fund"},{"orgOrder":0,"company":"Arthrosi Therapeutics","sponsor":"Guangrun Health Industry","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series D Financing","leadProduct":"AR882","moa":"URAT1","graph1":"Rheumatology","graph2":"Phase II","graph3":"Arthrosi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Capsule, Immediate Release","sponsorNew":"Arthrosi Therapeutics \/ Guangrun Health Industry","highestDevelopmentStatusID":"8","companyTruncated":"Arthrosi Therapeutics \/ Guangrun Health Industry"},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Engineered Urate Oxidase","moa":"Urate","graph1":"Rheumatology","graph2":"Phase II","graph3":"Allena Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allena Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allena Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Engineered Urate Oxidase","moa":"Urate","graph1":"Rheumatology","graph2":"Phase II","graph3":"Allena Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allena Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allena Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dyve Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"DYV700","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase II","graph3":"Dyve Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Dyve Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dyve Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Dyve Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Colchicine","moa":"||pH","graph1":"Rheumatology","graph2":"Phase II","graph3":"Dyve Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Transdermal Cream","sponsorNew":"Dyve Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dyve Biosciences \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Arthrosi Therapeutics

                            U.S.A arrow
                            AAN
                            Not Confirmed

                            Arthrosi Therapeutics

                            U.S.A arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AR882

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase II

                            Sponsor : Guangrun Health Industry

                            Deal Size : $75.0 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            Arthrosi Secures $75M in Series D Financing

                            Details : The company intends to use the net proceeds to fund the development of AR882, a highly potent and selective next-gen URAT1 inhibitor delivered in a once daily immediate release oral capsule, being developed for the treatment of gout.

                            Product Name : AR882

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 07, 2023

                            Lead Product(s) : AR882

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase II

                            Sponsor : Guangrun Health Industry

                            Deal Size : $75.0 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Jiangsu Atom Bioscience & Pharmaceutical

                            China arrow
                            AAN
                            Not Confirmed

                            Jiangsu Atom Bioscience & Pharmaceutical

                            China arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lingdolinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Atom Bioscience Announces Positive Results of Phase 2a China Clinical Trial of Its URAT1 Inhibitor for Chronic...

                            Details :

                            Product Name : ABP-671

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 03, 2023

                            Lead Product(s) : Lingdolinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Jiangsu Atom Bioscience & Pharmaceutical

                            China arrow
                            AAN
                            Not Confirmed

                            Jiangsu Atom Bioscience & Pharmaceutical

                            China arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lingdolinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Atom Bioscience to Present Final Data from its Positive Phase 2a Clinical Trial in Chronic Gout at American Co...

                            Details :

                            Product Name : ABP-671

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 11, 2022

                            Lead Product(s) : Lingdolinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Jiangsu Atom Bioscience & Pharmaceutical

                            China arrow
                            AAN
                            Not Confirmed

                            Jiangsu Atom Bioscience & Pharmaceutical

                            China arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lingdolinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase II

                            Sponsor : Xicheng Jinrui Equity Investment Fund

                            Deal Size : $45.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Atom Bioscience Raises $45 Million in Series C Round of Financing to Advance Development of Small Molecule Dru...

                            Details :

                            Product Name : ABP-671

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 01, 2022

                            Lead Product(s) : Lingdolinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase II

                            Sponsor : Xicheng Jinrui Equity Investment Fund

                            Deal Size : $45.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Jiangsu Atom Bioscience & Pharmaceutical

                            China arrow
                            AAN
                            Not Confirmed

                            Jiangsu Atom Bioscience & Pharmaceutical

                            China arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lingdolinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Atom Bioscience Announces Positive Phase 2a Results For Investigational New Drug to Treat Chronic Gout

                            Details :

                            Product Name : ABP-671

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 21, 2022

                            Lead Product(s) : Lingdolinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            LG Chem

                            South Korea arrow
                            AAN
                            Not Confirmed

                            LG Chem

                            South Korea arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tigulixostat

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            LG Chem Enters Final Stage of Clinical Development for New Gout Drug

                            Details : Results from US Phase 2 clinical trial—primary end point set at a challenging level confirmed the potential of LC350189 (tigulixostat) as a new gout treatment distinguished from pre-existing drugs, while also demonstrating safety similar to that of the...

                            Product Name : LC350189

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 08, 2022

                            Lead Product(s) : Tigulixostat

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Dyve Biosciences

                            U.S.A arrow
                            AAN
                            Not Confirmed

                            Dyve Biosciences

                            U.S.A arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DYV702,Colchicine

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dyve Biosciences Announces Phase 2 TARGETS Study of DYV702 for Pain Associated with Acute Gout Flares Showcase...

                            Details : Topical application of DYV702 significantly reduced pain intensity and duration of acute gout flare with higher overall response rates, faster time to resolution, improvements in physical function and reduction in rescue medication use.

                            Product Name : DYV702

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 06, 2022

                            Lead Product(s) : DYV702,Colchicine

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Allena Pharmaceuticals

                            U.S.A arrow
                            AAN
                            Not Confirmed

                            Allena Pharmaceuticals

                            U.S.A arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Engineered Urate Oxidase

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allena Pharmaceuticals Commences Dosing of Gout Patients in Second Phase 2a Trial of ALLN-346

                            Details : Allena recently completed a Phase 1b multiple ascending dose study of ALLN-346. The study included 18 healthy volunteers, who received either ALLN-346 or placebo (2:1 randomization) for seven days.

                            Product Name : ALLN-346

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            September 29, 2021

                            Lead Product(s) : Engineered Urate Oxidase

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Allena Pharmaceuticals

                            U.S.A arrow
                            AAN
                            Not Confirmed

                            Allena Pharmaceuticals

                            U.S.A arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Engineered Urate Oxidase

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allena Pharmaceuticals Receives Fast Track Designation from FDA for the Development of ALLN-346 for Chronic Tr...

                            Details : Company is developing ALLN-346 for the treatment of hyperuricemia and gout in the setting of advanced CKD, with a Phase 1 multiple ascending dose study recently completed and a Phase 2a program underway.

                            Product Name : ALLN-346

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            March 11, 2021

                            Lead Product(s) : Engineered Urate Oxidase

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Selecta Biosciences

                            U.S.A arrow
                            AAN
                            Not Confirmed

                            Selecta Biosciences

                            U.S.A arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegadricase

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase II

                            Sponsor : Swedish Orphan Biovitrum AB

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sobi and Selecta Announce Strategic Licensing Agreement for SEL-212, a Phase 3-ready Novel Treatment for Chron...

                            Details : This strategic licensing agreement is for SEL-212, a combination of Selecta's tolerogenic ImmTOR immune tolerance platform and a therapeutic uricase enzyme (pegadricase) for the treatment of chronic refractory gout.

                            Product Name : SEL-212

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            November 06, 2020

                            Lead Product(s) : Pegadricase

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase II

                            Sponsor : Swedish Orphan Biovitrum AB

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth